IRON SERIES: #1 BeLow Ferritin

Why iron deficiency hides in plain sight — and what your lab result isn't telling you.

The fatigue is the first thing you notice.

• The energy doesn't match the sleep.
• The 2pm crash arrives without permission.
• There's hair on the brush that wasn't there last year.
• Exercise you used to tolerate now sits heavier the day after.

None of this is dramatic. It's the quiet kind — the kind you've explained to yourself with the season of life, the workload, the kids, the weather.

Then you got the bloods done. The GP looked at the number, looked at you, said your iron is a little low. You also kept feeling tired. If you're a woman in Australia between the ages of 18 and 50, the chance that something on those bloods was actually iron-related is statistically high. The chance that it was caught — depending on the number, the threshold, and the year your lab last updated its reference range — is much lower.

This article is about the gap between the lab number and the body. Specifically, about ferritin: the marker most ordered, most relied on, and most easily misread. It's also about a quiet argument that has been running in haematology for over a decade — the argument about where the line for iron deficiency actually is.

The bodies that would know — the Royal College of Pathologists of Australasia, the WHO (World Health Organisation), Cochrane reviewers, the authors of the largest physiological-evidence papers — are not in agreement. The line keeps moving, and the direction has been one way: up. The article walks you through what that means in practice, for an Australian woman whose ferritin came back below 41, and was told everything looked fine.

The lab and the line

The Australian diagnostic threshold for iron deficiency is a ferritin level below 30 µg/L. Internationally, the evidence is more divided — and the trend has been to raise the line, not lower it.

Ferritin is the protein your body uses to store iron. Most of it sits in the liver, the spleen, and the bone marrow. A small fraction circulates in the blood. The amount in your blood reflects, in most circumstances, how much iron is held in your tissue stores. (We'll get to the times it doesn't.) When you do an “iron studies” panel, ferritin is the load-bearing number. Transferrin saturation, serum iron, and TIBC (Total Iron Binding Capacity) come along for context, but ferritin is the one a GP looks at first.

The reference range on your lab result — typically 15 to 200 µg/L for women, 30 to 300 for men in Australia — is a population range. It's the spread of values seen across the population that gave blood samples. It tells you whether your number is statistically common; it doesn't tell you whether your iron stores are adequate for your body to function well.

The Royal College of Pathologists of Australasia has been clear on this distinction since at least 2010, and re-confirmed it in their 2021 Iron Studies Standardised Reporting Protocol: a serum ferritin level below 30 µg/L for an adult is diagnostic of iron deficiency.¹ The Cochrane review that underpins much of the international position confirmed it: at the 30 µg/L cutoff, the test correctly identifies about four out of five people who actually have iron deficiency.² RCPA's own evidence base notes the numbers improve again at 41 µg/L, where the test catches almost all of them.

Internationally, the picture is wider. The WHO retained the historical threshold of <15 µg/L for women in its 2020 ferritin guideline, on the explicit grounds that the evidence wasn't strong enough yet to revise it.³ A 2021 paper in The Lancet Haematology used data from over 10,000 people to look at where iron-restricted red-blood-cell production actually begins, and converged on around 25 µg/L for non-pregnant women.⁴ A 2012 CMAJ trial used a different threshold again: it gave 198 women with unexplained fatigue and ferritin below 50 µg/L either oral iron or placebo for twelve weeks, and fatigue scores fell substantially more on iron than placebo.⁵

So: WHO at 15. RCPA at 30. Physiological evidence at 25. Symptomatic-fatigue threshold at 50. RCPA's own evidence base at 41. None of these is “wrong” — they're answering different questions. What they have in common is that the line keeps moving, and the direction has been one way: up.

If your bloods come back below 41, this is where the conversation lives.

When ferritin isn't telling the truth

If ferritin came back fine and CRP wasn't on the panel, the question hasn't been answered yet — it's been deferred.

Ferritin has a complication that doesn't show up on the lab printout. It's an acute-phase reactant. When the body is inflamed — by chronic inflammation, metabolic conditions, or a recent virus or infection — ferritin goes up.⁶ Your iron stores haven't actually risen; the marker has.

The BRINDA project, a 2017 re-analysis of 23 large surveys, modelled what happens when you correct for inflammation. As inflammation came out of the data, the prevalence of depleted iron stores rose from 4% to 30% in children, and from 6% to 29% in women.⁷ Inflammation correction added between 7 and 25 percentage points to estimated iron deficiency prevalence depending on the population.

This generalises to overweight physiology in a clinically important way. Researchers found that obese Mexican women had nearly twice the odds of iron deficiency, and obese children nearly four times the odds, at the same dietary iron intakes as non-obese women.⁸ A 2022 study in overweight pregnant women showed something more direct: despite comparable ferritin readings, fractional iron absorption was 43% lower in the third trimester.⁹ Iron was being absorbed and trafficked less efficiently in physiology that the lab couldn't see.

This is why most modern iron-status approaches don't treat ferritin as the only number. Transferrin saturation below 20% indicates iron-restricted red-blood-cell production regardless of where ferritin sits. Soluble transferrin receptor (a separate marker) isn't increased by inflammation, so combining it with ferritin can distinguish absolute iron deficiency from the iron sequestration that happens in chronic inflammation.¹⁰ Reticulocyte haemoglobin equivalent (RET-He), reported on most automated CBC machines within hours, has a useful cut off and is inflammation-resistant.¹¹

The phenotype that gets missed

Iron deficiency produces real, measurable symptoms before haemoglobin moves. The trial evidence supports it. Most clinical practice is still catching up.

The clinical framing that makes the most sense of all this is in Pasricha et al.'s 2021 Lancet seminar. Iron deficiency is a continuum: when iron starts running low, the body redirects what it has, and red-blood-cell production is the first priority on the list. Haemoglobin holds steady until almost everything else has been depleted. By the time anaemia is on the lab report, iron deficiency has already been present, and producing real-world symptoms, for some time. Clinical and functional impairments can occur in the absence of anaemia.¹²

The literature has a name for this pattern — non-anaemic iron deficiency, or NAID — and the better-quality evidence supports it as a real, defined phenotype that responds to iron repletion.

The Vaucher trial above is one piece. A 2011 trial in Blood gave 90 premenopausal women with low ferritin either intravenous iron or placebo. The fatigue benefit — 82% improved on iron versus 47% on placebo, and the improvement on iron was more than four times the improvement on placebo.¹³

A 2018 systematic review pooled 18 trials with a combined 1,170 participants. The headline finding is the most honest one in the field: iron repletion in non-anaemic iron deficiency produced a clinically meaningful benefit on subjective fatigue, and the result was consistent across studies. It produced no meaningful benefit on objective VO₂max.¹⁴ How women feel improves. What their cardiopulmonary system can do, in this evidence base, does not. What the literature actually supports is the part you came in with — feeling more like yourself across the day. A parallel review in 2016 put it most directly: NAID is a disease in its own right, deserving recognition, even when haemoglobin reads normal.¹⁵

How women feel improves. What their cardiopulmonary system can do, in this evidence base, does not. What the literature actually supports is the part you came in with — feeling more like yourself across the day.

A related phenotype worth a brief note: restless legs syndrome, where peripheral ferritin can read normal while brain iron is genuinely low. The 2018 IRLSSG consensus guideline endorses iron repletion at peripheral ferritin levels much higher than the standard diagnostic threshold, and a 2025 meta-analysis confirmed the symptom benefit of intravenous iron at scale.^{16, 17} Brain iron and blood iron are not the same conversation.

Who's most at risk in Australia

If your ferritin came back at 28 µg/L, you are in the company of approximately 1 in 3 Australian women aged 18 to 39.

The phenotypes that flow into this prevalence weight heavily toward reproductive-age women, but each is worth knowing in its own right.

If your ferritin came back at 28 µg/L, you are in the company of approximately 1 in 3 Australian women aged 18 to 39.

Heavy menstrual bleeding (HMB) affects approximately one in three reproductive-age women, and is one of the most underdiagnosed drivers of iron loss.¹⁸ Australian longitudinal data show prevalence rising from 17.6% at age 22 to 39.3% at age 48 — more than a doubling across the reproductive lifespan.¹⁹ HMB is normalised to the point that the majority of women experiencing it never have iron status checked.

Pregnancy raises the absorbed-iron requirement from approximately 1 mg/day in the first trimester to 7.5 mg/day in the third. Adequate iron stores at conception require around 500 mg of body iron — a level only 15 to 20% of reproductive-age women achieve.²⁰ A 2024 paper in Blood Advances derived trimester-specific physiological ferritin thresholds well above the WHO 15 floor: 25.8 µg/L in the first trimester, 18.3 in the second, 19.0 in the third.²¹

Postpartum recovery is slower than commonly assumed. A systematic review of 15 trials found haemoglobin around 0.9 g/dL higher with intravenous iron than oral at six weeks postpartum, indicating that with oral repletion, return to normal haemoglobin often requires six or more weeks — and ferritin recovery lags behind haemoglobin by months.²² For women who have had iron infusions, this is the maintenance window where the operational question shifts from how to climb back to how to hold the line.

Athletes, especially endurance athletes, run an elevated risk through three mechanisms: footstrike haemolysis, the exercise-hepcidin axis (where exercise raises the body's iron-trafficking hormone for several hours afterwards), and dilutional plasma-volume effects that accumulate across hard training weeks. Female prevalence runs at 15 to 35% across athlete cohorts, male prevalence at 5 to 11%.²³

Vegetarians and vegans carry a measurable iron-status deficit. A 2018 systematic review found average ferritin almost 30 µg/L lower than in omnivores, with the effect larger in men than women.²⁴ The mechanism is straightforward: non-haem-only intake combined with the bioavailability ceiling imposed by phytate and polyphenols.

Older adults present anaemia of a different character — multi-aetiological, often with chronic inflammation overlapping absolute iron deficiency, where the standard ferritin thresholds underdetect the problem in the same way they do in obesity.²⁵

The Australian numbers. In a 2020 population-based survey of 736 Australian women aged 18 to 39, 34.8% had ferritin below 30 µg/L — the RCPA threshold.²⁶ Reporting more than two days of heavy menstrual bleeding was an independent predictor. The ABS Australian Health Survey of 2011–12 put the prevalence of iron stores below the WHO 15 µg/L floor at approximately 12% of women aged 16–44 versus 1–2% of men.²⁷ Among Australian children, the OzFITS 2021 study found 90% of infants 6–11.9 months and approximately 25% of toddlers 12–24 months had iron intakes below the EAR.²⁸ Around 40% of girls aged 14–18 have inadequate iron intake.²⁹

Daily requirements

NRVs from the NHMRC Nutrient Reference Values for Australia and New Zealand.³⁰

For nutrition information panels and label calculations in Australia, FSANZ Schedule 1 sets a single average adult RDI of 12 mg/day, used regardless of sex.

A note worth keeping in mind: approximately 0.5% of the Australian population of European ancestry is homozygous for hereditary haemochromatosis and susceptible to iron overload at normal intakes. People in this group should avoid iron supplements and highly iron-fortified foods unless under specialist guidance.

If you're being treated

Most iron repletion in Australia starts with oral ferrous sulphate, prescribed at one or two tablets a day. It works, but it has a tolerability problem the literature has been quantifying for over a decade. A systematic review of 43 trials found ferrous sulphate was more than twice as likely to cause gastrointestinal side effects as placebo.³¹

There's a more interesting development in dosing strategy. In 2015, Moretti and colleagues showed in Blood that a single dose of 60 mg of elemental iron or higher acutely raises serum hepcidin and reduces fractional iron absorption from the next day's dose by 35 to 45%.³² In other words, dosing every day partially blocks itself.

In other words, dosing every day partially blocks itself.

A 2017 Lancet Haematology trial confirmed the clinical implication: cumulative fractional iron absorption was 21.8% on alternate-day dosing versus 16.3% on consecutive-day dosing.³³ The largest and longest trial to date — a six-month study in 150 women — found ferritin endpoints similar between alternate-day and daily at the same cumulative dose, but gastrointestinal side-effect rates more than 50% higher on consecutive-day dosing.³⁴ A 2025 expert consensus from OHSU endorsed alternate-day oral dosing as a reasonable option.³⁵ It isn't yet universal standard care in Australian primary practice — daily ferrous sulphate remains the default — but it's an evidence-based option to discuss with a clinician where tolerability is the limiting factor.

Time to repletion. With oral iron, haemoglobin typically rises about 1 g/dL every two to four weeks once therapeutic absorption is established. Ferritin recovery takes longer — usually 8 to 12 weeks for moderate iron-deficiency anaemia, and considerably longer for severe deficiency or full tissue-store repletion, especially under continued losses.¹²

Intravenous iron is preferred when oral has failed, is not tolerated, or in conditions where rapid repletion is clinically necessary. A 2015 systematic review of 103 trials covering more than 10,000 patients on intravenous iron found serious adverse event risk at the same level as the comparison treatments tested (mostly oral iron).³⁶

Wholefood and where it fits

The wholefood story for iron has some real evidence and some genuine gaps.

The real evidence: a 2025 systematic review pooled 10 trials of red-meat-based interventions in adults with normal or suboptimal iron status. Over 16 weeks or more, ferritin rose by approximately 5.6 µg/L on average, and haemoglobin by 2.36 g/L. Modest, statistically meaningful, and useful for maintenance — supporting iron status over time.³⁷

The genuine gap: there is very little direct evidence specific to organ meats and ferritin recovery in established iron deficiency. We could not identify a 2024–2026 randomised trial testing liver, spleen, or other organs against a clinical-deficiency endpoint. The honest synthesis is the one we'd offer a friend asking the same question:

Wholefood iron is well placed to support iron-status maintenance — particularly for someone whose ferritin is currently adequate, who has known long-term losses (HMB, athletic stress, post-infusion maintenance), or who has tolerability problems with synthetic iron. Wholefood iron is not established in clinical-trial evidence as a primary route for closing established iron deficiency.

Iron is one of those nutrients where the form matters as much as the amount. It's also where the cofactors matter — copper, B12, folate, vitamin A — and that's a story we'll cover properly in Article 4 of this series.

Bringing it all together

Iron deficiency, in the modern Australian context, is more often a question of recognition than of treatment. The treatment is well understood. The recognition is where the system tends to fall short — partly because the lab reference range for women still flags only the most depleted cases, partly because RCPA's clinical position hasn't fully filtered through to the way “your iron is fine” gets said in a five-minute consultation, and partly because ferritin itself is unreliable in inflammation and overweight physiology, where many of the bodies that need it most don't get a clean reading.

If you've been told your iron is fine and you don't feel fine, the next conversation should be with a clinician who knows the threshold debate, who orders a CRP alongside ferritin, who looks at transferrin saturation when ferritin is ambiguous, and who treats the symptomatic phenotype as a real one. Wholefood iron has a role — for maintenance, for tolerability, for the slow hold against the kind of long-haul iron deficiency that comes with being a woman in your reproductive years or with heavy bleeding. It's not a substitute for diagnosis.

The most useful thing we can offer is a slightly different question to bring to the appointment. Not is my iron fine. Not even is my ferritin in range. Try: what's my ferritin number, and where does that sit relative to RCPA's threshold of 30 — and the symptomatic threshold of 50? The answer is yours from there.

This article provides general nutrition information only and is not intended as medical advice. If you have concerns about your iron levels, consult a qualified health practitioner.

In a few weeks: tolerability, dosing, and why the standard advice on oral iron has been slow to update.

References

1. Royal College of Pathologists of Australasia. Iron Studies Standardised Reporting Protocol, 2nd Edition. Sydney: RCPA; November 2021. https://www.rcpa.edu.au/Library/Practising-Pathology/NCRPQF/Docs/Iron-Studies-Standardised-Reporting-Protocol

2. Garcia-Casal MN, Pasricha S-R, Martinez RX, Lopez-Perez L, Peña-Rosas JP. Serum or plasma ferritin concentration as an index of iron deficiency and overload. Cochrane Database Syst Rev. 2021;5(5):CD011817. https://doi.org/10.1002/14651858.CD011817.pub2

3. World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: WHO; 2020. https://www.who.int/publications/i/item/9789240000124

4. Mei Z, Addo OY, Jefferds ME, Sharma AJ, Flores-Ayala RC, Brittenham GM. Physiologically based serum ferritin thresholds for iron deficiency in children and non-pregnant women: a US National Health and Nutrition Examination Surveys serial cross-sectional study. Lancet Haematol. 2021;8(8):e572–e582. https://doi.org/10.1016/S2352-3026(21)00168-X

5. Vaucher P, Druais P-L, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. 2012;184(11):1247–1254. https://doi.org/10.1503/cmaj.110950

6. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50. https://doi.org/10.1182/blood-2018-06-856500

7. Namaste SM, Rohner F, Huang J, et al. Adjusting ferritin concentrations for inflammation: BRINDA project. Am J Clin Nutr. 2017;106(Suppl 1):359S–371S. https://doi.org/10.3945/ajcn.116.141762

8. Cepeda-Lopez AC, Osendarp SJM, Melse-Boonstra A, et al. Sharply higher rates of iron deficiency in obese Mexican women and children predicted by obesity-related inflammation rather than by differences in dietary iron intake. Am J Clin Nutr. 2011;93(5):975–983. https://doi.org/10.3945/ajcn.110.005439

9. Stoffel NU, Zimmermann MB, Cepeda-Lopez AC, et al. Maternal iron kinetics and maternal–fetal iron transfer in normal-weight and overweight pregnancy. Am J Clin Nutr. 2022;115(4):1166–1179. https://doi.org/10.1093/ajcn/nqab406

10. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. https://doi.org/10.1056/NEJMra1401038

11. Auerbach M, Staffa SJ, Brugnara C. Using reticulocyte hemoglobin equivalent (RET-He) as a marker for iron deficiency and responsiveness to iron therapy. Mayo Clin Proc. 2021;96(6):1510–1519. https://doi.org/10.1016/j.mayocp.2020.10.042

12. Pasricha S-R, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233–248. https://doi.org/10.1016/S0140-6736(20)32594-0

13. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222–3227. https://doi.org/10.1182/blood-2011-04-346304

14. Houston BL, Hurrie D, Graham J, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open. 2018;8(4):e019240. https://doi.org/10.1136/bmjopen-2017-019240

15. Pratt JJ, Khan KS. Non-anaemic iron deficiency — a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol. 2016;96(6):618–628. https://doi.org/10.1111/ejh.12645

16. Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27–44. https://doi.org/10.1016/j.sleep.2017.11.1126

17. Khan A, Kumar H, Rai KD, et al. Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis. Front Neurol. 2025;15:1503342. https://doi.org/10.3389/fneur.2024.1503342

18. Munro MG, Mast AE, Powers JM, et al. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023;229(1):1–9. https://doi.org/10.1016/j.ajog.2023.01.017

19. Wilson L, Mishra GD, Loxton D, Tooth L. Women who experience heavy menstrual bleeding: prevalence and characteristics from young adulthood to midlife, Australia, 2000–2021: a longitudinal cohort survey study. Med J Aust. 2025;222(4):191–197. https://doi.org/10.5694/mja2.52596

20. Milman N. Iron in pregnancy: how do we secure an appropriate iron status in the mother and child? Ann Nutr Metab. 2011;59(1):50–54. https://doi.org/10.1159/000332129

21. Mei Z, Addo OY, Jefferds ME, et al. Physiologically based trimester-specific serum ferritin thresholds for iron deficiency in US pregnant women. Blood Adv. 2024;8(14):3745–3753. https://doi.org/10.1182/bloodadvances.2024013460

22. Sultan P, Bampoe S, Shah R, et al. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(1):19–29.e3. https://doi.org/10.1016/j.ajog.2018.12.016

23. Sim M, Garvican-Lewis LA, Cox GR, et al. Iron considerations for the athlete: a narrative review. Eur J Appl Physiol. 2019;119(7):1463–1478. https://doi.org/10.1007/s00421-019-04157-y

24. Haider LM, Schwingshackl L, Hoffmann G, Ekmekcioglu C. The effect of vegetarian diets on iron status in adults: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58(8):1359–1374. https://doi.org/10.1080/10408398.2016.1259210

25. Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018;131(5):505–514. https://doi.org/10.1182/blood-2017-07-746446

26. Islam RM, Bell RJ, Skiba MA, Davis SR. Iron insufficiency among young Australian women: a population-based survey. Intern Med J. 2020;50(4):420–426. https://doi.org/10.1111/imj.14397

27. Australian Bureau of Statistics. Australian Health Survey: Biomedical Results for Nutrients, 2011–12 — Iron. Canberra: ABS; 2013. https://www.abs.gov.au/statistics/health/health-conditions-and-risks/australian-health-survey-biomedical-results-nutrients/latest-release

28. Moumin NA, Netting MJ, Golley RK, et al. Usual nutrient intake distribution and prevalence of inadequacy among Australian children 0–24 months: findings from the Australian Feeding Infants and Toddlers Study (OzFITS) 2021. Nutrients. 2022;14(7):1381. https://doi.org/10.3390/nu14071381

29. Australian Institute of Health and Welfare. Nutrition across the life stages. Canberra: AIHW; 2018. Cat. no. PHE 227. https://www.aihw.gov.au/reports/food-nutrition/nutrition-across-the-life-stages

30. National Health and Medical Research Council. Nutrient Reference Values for Australia and New Zealand — Iron. Canberra: NHMRC; 2006. https://www.eatforhealth.gov.au/sites/default/files/2022-04/n35-iron_0.pdf

31. Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117383. https://doi.org/10.1371/journal.pone.0117383

32. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126(17):1981–1989. https://doi.org/10.1182/blood-2015-05-642223

33. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524–e533. https://doi.org/10.1016/S2352-3026(17)30182-5

34. von Siebenthal HK, Moretti D, Zimmermann MB, Stoffel NU. Alternate day versus consecutive day oral iron supplementation in iron-depleted women: a randomized double-blind placebo-controlled study. EClinicalMedicine. 2023;65:102286. https://doi.org/10.1016/j.eclinm.2023.102286

35. Benson AE, Lo JO, Caughey AB, et al. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. Lancet Haematol. 2025;12(5):e376–e388. https://doi.org/10.1016/S2352-3026(25)00038-9

36. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12–23. https://doi.org/10.1016/j.mayocp.2014.10.007

37. McManus L, Veras K, Faria VS, Manninen M, Egan B. Effect of increasing red meat intake on iron status in adults with normal and suboptimal iron status: a systematic literature review and meta-analysis of intervention studies. Nutr Rev. 2025;83(8):1389–1401. https://doi.org/10.1093/nutrit/nuaf016